Get the Stockscreener App
14.07
3.99%
0.54
Keros Therapeutics Inc stock is traded at $14.07, with a volume of 1.35M.
It is up +3.99% in the last 24 hours and up +21.08% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$13.53
Open:
$13.42
24h Volume:
1.35M
Relative Volume:
0.97
Market Cap:
$516.76M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.7427
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
+14.95%
1M Performance:
+21.08%
6M Performance:
-76.97%
1Y Performance:
-76.26%
1-Day Range:
$13.42
$14.20
1-Week Range:
$11.93
$14.20
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
14.07 | 516.76M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Altium Capital Management LLC Has $2.77 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
How the (KROS) price action is used to our Advantage - news.stocktradersdaily.com
Vanguard Group Inc. Has $30.98 Million Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
124,620 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Federated Hermes Inc. - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Alliancebernstein L.P. Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Adar1 Capital Management, Llc Purchases 934,258 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) Stock - MarketBeat
Keros Therapeutics enters agreement with Pontifax - Investing.com Australia
Keros Therapeutics enters agreement with Pontifax By Investing.com - Investing.com Canada
Norges Bank Invests $1.03 Million in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Truist Financial Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $25.00 - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by ADAR1 Capital Management LLC - MarketBeat
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% - MSN
Adar1 partners increases stake in Keros Therapeutics with $9.1m purchase - Investing.com Canada
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price - Benzinga
Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation - Seeking Alpha
Keros Therapeutics (KROS) Reports Positive Phase 1 Results for K - GuruFocus
Keros Therapeutics (KROS) Shows Potential for Upside - GuruFocus
Keros Therapeutics (KROS) Surges Amid Strategic Review and Poiso - GuruFocus
Keros Therapeutics (KROS) Shows Potential with Analyst Optimism - GuruFocus
Adar1 capital management increases stake in Keros Therapeutics with $328k purchase - Investing.com
Keros Therapeutics (KROS) Initiates Strategic Review and Adopts Rights Plan | KROS Stock News - GuruFocus
Keros Therapeutics Announces Review of Strategic Alternatives | KROS Stock News - GuruFocus
Bryce Point Capital LLC Invests $445,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics Explores Major Strategic Alternatives With Share Price Jump - Finimize
Keros Therapeutics Shares Rise After Board Initiates Review of Strategic Alternatives - marketscreener.com
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan - Benzinga
Keros Therapeutics considers sale amid investor pressure - Yahoo Finance
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed - MSN
Keros Therapeutics adopts poison pill as it explores options, including sale - MSN
Keros Therapeutics stock jumps on strategic review, potential sale By Investing.com - Investing.com Canada
Keros Therapeutics Considers Sale Amid Strategic Review Process - Finimize
Keros Therapeutics adopts poison pill as shareholders seek control - MSN
Keros Therapeutics Board Initiates Review of Strategic Alternatives - marketscreener.com
Keros stock climbs after strategic review (KROS:NASDAQ) - Seeking Alpha
Keros Therapeutics Announces Review of Strategic Alternatives - The Manila Times
Keros Therapeutics rises after adoption of 'poison pill' plan, review of strategic options - TradingView
Keros reviewing strategic alternatives, adopts shareholder rights plan - TipRanks
Keros Therapeutics adopts 'poison pill' plan - TradingView
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):